Dexcom reaffirms CGM benefits for all people with diabetes and continues momentum toward earlier stage intervention and preventative care at ADA 2026.
Article excerpt
Highlighted: the sentence this signal was extracted from
Dexcom reaffirms CGM benefits for all people with diabetes and continues momentum toward earlier stage intervention and preventative care at ADA 2026. * Highly anticipated presentation of results from the CONNECT randomized control trial will be presented during the ADA Scientific Sessions conference on Saturday, June 6 at 1:45 p.m. CDT. * Early access launch of a completely reimagined Stelo app will define a new era of glucose tracking for all people not on insulin seeking better health. * Acquisition of Nutrisense will strengthen Dexcom's ability to provide personalized nutrition education and coaching to improve diabetes management and help further establish CGM as an effective tool for preventative care. SAN DIEGO-(BUSINESS WIRE)-DexCom, Inc. (NASDAQ:DXCM) will present new clinical findings, product advancements and strategic business initiatives reinforcing its commitment to improving care for people with all types of diabetes and ushering in a new era of early stage CGM intervention and preventative care at the American Diabetes Association's Scientific Sessions in New Orleans, June 5-8, 2026. "Dexcom has built a legacy of innovation within the diabetes space and as we look to the future, expanding access and developing new CGM solutions to better support early-stage intervention and preventative care are top priorities," said Jake Leach, president and CEO at Dexcom...
Keep reading with a free account
The rest of this article, and every signal for Dexcom, is in your free account.
